Prof. Seigo Kinuya

Department of Nuclear Medicine

Kanazawa University, Japan

Professor

Email: [email protected]

Qualifications

1994 Board certification, Japanese Board of Nuclear Medicine

1993 Board certification, Japanese Board of Radiology

1990 Ph.D., Kanazawa University

1986 M.D., Kanazawa University

Publications (selected)

1. Sengoku T, Oshima T, Takata Y, et al. Characteristics of lower limb skeletal muscle activity during walking in patients with knee osteoarthritis and knee extensor weakness: Comprehensive assessment using positron emission tomography[J]. Journal of Electromyography and Kinesiology, 2025: 103085.
2. Tamamura K, Akita Y, Mishiro K, et al. Development of a Theranostic Agent for Bone Metastases: Integration of Nuclear Medicine Imaging and Boron Neutron Capture Therapy (BNCT)[J]. Molecular Pharmaceutics, 2025, 22(9): 5546-5554.
3. Sugitani I, Kiyota N, Ito Y, et al. The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery[J]. Endocrine Journal, 2025, 72(5): 545-635.
4. Echigo H, Munekane M, Fuchigami T, et al. Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51(9): 2663-2671.
5. Chen Z, Wakabayashi H, Kuroda R, et al. Radiation exposure lymphocyte damage assessed by γ-H2AX level using flow cytometry[J]. Scientific Reports, 2024, 14(1): 4339.
6. Echigo H, Mishiro K, Munekane M, et al. Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At)[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51(2): 412-421.
7. Urbain J L, Scott A M, Lee S T, et al. Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear medicine[J]. Journal of Nuclear Medicine, 2023, 64(6): 986-991.
8. Zhang X, Wakabayashi H, Hiromasa T, et al. Recent advances in radiopharmaceutical theranostics of pheochromocytoma and paraganglioma[C]//Seminars in Nuclear Medicine. WB Saunders, 2023, 53(4): 503-516.
9. Mishiro K, Imai S, Ematsu Y, et al. RGD peptide-conjugated dodecaborate with the Ga-DOTA complex: a preliminary study for the development of theranostic agents for boron neutron capture therapy and its companion diagnostics[J]. Journal of Medicinal Chemistry, 2022, 65(24): 16741-16753.
10. Ukon N, Higashi T, Hosono M, et al. Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy[J]. Annals of Nuclear Medicine, 2022, 36(8): 695-709.
11. Mishiro K, Nishii R, Sawazaki I, et al. Development of radiohalogenated osimertinib derivatives as imaging probes for companion diagnostics of osimertinib[J]. Journal of Medicinal Chemistry, 2022, 65(3): 1835-1847.
12. Ogawa K, Echigo H, Mishiro K, et al. 68Ga-and 211At-Labeled RGD peptides for radiotheranostics with multiradionuclides[J]. Molecular Pharmaceutics, 2021, 18(9): 3553-3562.
13. Watabe T, Hosono M, Kinuya S, et al. Manual on the proper use of sodium astatide ([211At] NaAt) injections in clinical trials for targeted alpha therapy[J]. Annals of Nuclear Medicine, 2021, 35(7): 753-766.
14. Satoh Y, Kawamoto M, Kubota K, et al. Clinical practice guidelines for high-resolution breast PET, 2019 edition[J]. Annals of nuclear medicine, 2021, 35(3): 406-414.
15. Effendi N, Mishiro K, Shiba K, et al. Development of radiogallium-labeled peptides for platelet-derived growth factor receptor β (PDGFR β) imaging: Influence of different linkers[J]. Molecules, 2020, 26(1): 41.
16. Fawwaz M, Mishiro K, Nishii R, et al. Synthesis and fundamental evaluation of radioiodinated rociletinib (CO-1686) as a probe to lung cancer with L858R/T790M mutations of epidermal growth factor receptor (EGFR)[J]. Molecules, 2020, 25(12): 2914.
17. Okuda K, Nakajima K, Yoneyama H, et al. Impact of iterative reconstruction with resolution recovery in myocardial perfusion SPECT: phantom and clinical studies[J]. Scientific reports, 2019, 9(1): 19618.
18. Kato S, Demura S, Matsubara H, et al. Utility of bone SPECT/CT to identify the primary cause of pain in elderly patients with degenerative lumbar spine disease[J]. Journal of orthopaedic surgery and research, 2019, 14(1): 185.
19. Ogawa K, Takeda T, Mishiro K, et al. Radiotheranostics coupled between an At-211-labeled RGD peptide and the corresponding radioiodine-labeled RGD peptide[J]. Acs Omega, 2019, 4(3): 4584-4591.
20. Kayano D, Kinuya S. Current consensus on I-131 MIBG therapy[J]. Nuclear medicine and molecular imaging, 2018, 52(4): 254-265.
21. Hosono M, Ikebuchi H, Nakamura Y, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy[J]. Annals of nuclear medicine, 2018, 32(3): 217-235.
22. Yoneyama H, Nakajima K, Okuda K, et al. Reducing the small-heart effect in pediatric gated myocardial perfusion single-photon emission computed tomography[J]. Journal of Nuclear Cardiology, 2017, 24(4): 1378-1388.

Profile Details

https://ridb.kanazawa-u.ac.jp/public/detail_en.php?id=2858
https://www.researchgate.net/profile/Seigo-Kinuya
https://scholar.google.com/citations?user=hz2ON5YAAAAJ&hl=ja

WoS ResearcherID: FFU-2888-2022